Osmotic Therapy for Patients With Severe Subarachnoid Hemorrhage
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Subarachnoid Hemorrhage, Traumatic. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Practice of Osmotherapy in Severe SubArachnoid Hemorrhage Patients: Multicenter Observational Study (OSMO-SAH Study)
Overview
The goal of this prospective multi-center observational study is to learn about the osmotic therapy in severe subarachnoid hemorrhage (SAH). The main question\[s\] it aims to answer are: • whether the two osmotic therapy, 20% mannitol and 10% hypertonic saline(HTS), under the same osmotic equivalent, has similar influence on the outcome of SAH patients? Participants will be given proper treatment according to local expert consensus, including the choice of osmotic medicine. Investigators just record and analyse the data, compare mannitol group and HTS group to see if the outcome of latter is not worse than the former.
Primary outcome measures
- modified Rankin score [Time frame: 1 month after ictus]
- modified Rankin score [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- ①age ≥18； ②aneurysmal subarachnoid hemorrhage; ③Hunt-Hess 3-5级
Exclusion criteria
- previous cranial decompression surgery, cerebrospinal fluid leakage or drainage,
- bilateral pupils fixed or dilated,
- hemodynamic instability,
- hemoglobin < 8g / L,
- serum osmolality > 320 mOsm / L,
⑥ combined with severe organ dysfunction (cardiac, pulmonary, hepatic, renal and so on);
⑦ serious electrolyte disorders (serum sodium concentration <125 mmol / L or >170 mmol / L), and difficult to correct within limited time;
⑧ serious acid-base balance disorders, and difficult to correct within limited time;
⑨ use of mannitol or HSS within previous six hours;
⑩ being pregnant.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Xuanwu Hospital — Beijing
Publications
- Jiang L, Qi M, Xu Y, Qu X, Chen W, Cheng W, Zhao H, Shang F, Fu X, Wang C, Jiang R, Wang N. Hyperosmolar therapy for severe subarachnoid haemorrhage: a protocol for a multicentre prospective observational study (OSMO-SAH study). BMJ Open. 2025 Jul 25;15(7):e099008. doi: 10.1136/bmjopen-2025-099008. PMID 40713038
Identifiers
NCT: NCT05858060 · XWNeurosurgicalICU